BIRC5 and breast cancer: BIRC5 or survivin (Fig. 3b), a target of TP53 is an anti-apoptotic molecule that has been previously linked to the development and progression of breast cancer and the emergence of drug resistance, as well as with tumorigenesis in other cancer types [30–32].